Daily scan of every earnings reaction moving 20% or more, either direction. Ranked within each column by mismatch -- overreactions and mixed calls first, clean justified moves last -- so the ones worth reading first are on top.
FGI — FGI Industries Ltd. (+85.8%)
FGI Industries reported adjusted EPS of $0.60 versus a consensus estimate of $0.10—a massive 500% beat—but the headline numbers reveal a far more modest operational story: revenue of $31.9M missed estimates by 5.8% ($33.85M expected), while the core business showed only 2.9% year-over-year growth. The EPS beat stems primarily from a turnaround in the prior-year quarter (which reported a $0.61 loss), improved gross margins (33.4% vs. 28.1% YoY, a 530 bps gain driven partly by tariff recoveries buried in COGS), and lower operating expenses, rather than robust top-line momentum. Management reaffirmed full-year 2026 guidance of $134–141M revenue and $0.7–2.5M adjusted operating income—ranges that imply modest mid-single-digit growth and flat-to-low profitability—while acknowledging "uncertain" industry conditions, tariff headwinds, and declining sales in Canada (-24.5%) and Europe (-21.0%). An 85.8% stock rally on a 5.8% revenue miss and reaffirmed (not raised) guidance, even with an outsized EPS beat driven largely by lapping a prior loss, appears disconnected from the underlying business trajectory; the move prices in optimism well beyond what the operational data and forward guidance support.
View FGI →GXAI — Gaxos.ai Inc. (+50.5%)
Gaxos.ai reported second-quarter revenue of $2.46 million, crushing analyst estimates of $1.80 million for a 36.5% beat, while EPS came in flat at -$0.15 versus expectations (0% surprise). The headline story is impressive: revenue surged 1,337% year-over-year and 35.8% sequentially, with marketing efficiency improving materially—revenue per advertising dollar climbed 20% to $0.78, and the company's ad spend grew only 13.5% while revenue jumped 35.8%. However, a 50.5% stock rally on a revenue beat of that magnitude, combined with flat EPS, appears disconnected from fundamentals. The company is still unprofitable (losing $0.15 per share), advertising expense at 128% of revenue signals the business is not yet self-sustaining, and the near-term growth narrative hinges on continued disciplined ad spending rather than profitability inflection. While the marketing efficiency gains and 13× YoY growth are real and noteworthy, they do not justify a 50% single-day move when combined with persistent losses and margins still deeply underwater.
View GXAI →ARX — Accelerant Holdings (+44.7%)
Accelerant reported solid Q2 2026 results: exchange written premium grew 23% YoY to $1.32B, adjusted net income surged 165% to $70M, and adjusted EPS jumped 146% to $0.32 (vs. $0.13 prior year), while adjusted EBITDA margin expanded 160 basis points to 30.6%. However, the 44.7% stock rally appears disproportionate to the operational beat itself, since the company explicitly stated it will not provide Q3 or full-year 2026 guidance due to the pending Thoma Bravo acquisition announcement—making forward visibility opaque. The dramatic move is almost entirely attributable to the takeout deal at an undisclosed price rather than the earnings results, which, while strong on growth metrics, show deceleration in the core premium growth rate (23% this quarter vs. 42% in Q2 2025) and don't justify a 45% single-day jump on fundamentals alone. Without knowing the acquisition price or deal terms, it's impossible to assess whether shareholders are fairly compensated, but the stock reaction conflates operational momentum with M&A arbitrage.
View ARX →CURI — CuriosityStream Inc. (+29.3%)
CuriosityStream crushed Q2 expectations with EPS of $0.15 versus $0.0375 consensus—a 300% beat—while revenue of $23.2M edged estimates by ~9%, but the real catalyst was transformational profitability: net income surged 1,033% to $8.9M and adjusted EBITDA jumped 276% to $11.4M, marking the sixth consecutive profitable quarter. Licensing revenue nearly doubled to $14.1M (+48%) on AI training deals and traditional media partnerships, gross margin expanded to 72.8% from 53.4% year-over-year, and management raised full-year guidance to $77–$82M revenue and $18–$22M adjusted EBITDA, signaling a durable business inflection. While a 300% EPS beat would normally justify a 25–35% move on its own, the combination of record profitability, margin expansion, a strengthened guidance range, and demonstrated licensing traction with AI companies suggests the market is pricing in both Q2's magnitude and a genuine structural improvement to the earnings power, not merely a beat-driven pop. The 29% rally appears proportionate to a company transitioning from subscale to profitable, with visible revenue leverage and new revenue streams materializing.
View CURI →HLIT — Harmonic Inc. (+24.0%)
Harmonic crushed expectations with a 42.6% EPS beat ($0.24 actual vs. $0.1683 estimate) on a 10.3% revenue beat ($133.5M actual vs. $120.9M estimate), but the real catalyst was the strategic transformation and forward guidance. The company completed its Video business divestiture, generating $137.9M in proceeds to reach $231.9M cash, and pivoted to a pure-play broadband pure-play with accelerating 54% year-over-year revenue growth driven by 44% Rest-of-Market growth and a fortress backlog of $587.6M (up 71% YoY). Management raised full-year 2026 guidance to $505M–$525M revenue and $0.44–$0.53 EPS (non-GAAP $0.67–$0.75), implying mid-point growth of 28–35% and positioning the company as a high-growth, capital-light broadband infrastructure play with meaningful operating leverage. A 24% rally on a 43% EPS beat, a strategic deleveraging event, accelerating organic growth, and raised guidance across all metrics is proportionate to a company that has shed drag, doubled down on its highest-conviction segment, and signaled sustained momentum into H2 2026.
View HLIT →OMER — Omeros Corporation (+21.1%)
Omeros reported YARTEMLEA gross revenues of $32.2 million in Q2 2026, up 190% sequentially from $11.1 million in Q1—a dramatic acceleration in the commercial launch of its first-in-class TA-TMA treatment. On a non-GAAP basis (excluding derivative mark-to-market gains), adjusted net income was $0.02 per share for Q2 versus a loss of $0.24 per share in Q1, representing a significant swing to profitability and demonstrating the drug's strong early commercial traction and margin structure. The company also achieved meaningful balance-sheet improvements, including a 43% reduction in convertible debt principal ($30.5M repurchased), elimination of $8.6M in future interest payments, and strategic CMS New Technology Add-on Payment (NTAP) status effective October 2026 that will support hospital reimbursement. A 190% sequential revenue jump on a newly approved commercial product, combined with the path to profitability, major regulatory wins (J-code and NTAP), and a strengthened capital structure, provides substantial operational validation for the 21% stock rally.
View OMER →CLBT — Cellebrite DI Ltd. (-27.3%)
Cellebrite reported a substantial 78.6% EPS beat ($0.11 actual vs. $0.062 estimate) alongside a razor-thin revenue miss of just 0.6% ($131.1M actual vs. $131.9M estimate), yet the stock plummeted 27.3%. The earnings surprise was genuinely impressive on the bottom line—nearly 79% above consensus—while revenue essentially met expectations, suggesting operational leverage and margin expansion rather than fundamental deterioration. A nearly 80% EPS beat driving a 27% stock decline represents a severe disconnect; typically, a beat of that magnitude would warrant a positive or at worst muted reaction unless accompanied by sharply reduced guidance or major business headwinds that the provided sources do not document. The available news flow contains no CLBT-specific guidance reductions, margin warnings, contract losses, or strategic shifts—instead offering only general industry commentary about smartphone costs and AI demand trends affecting much larger competitors. Without substantive negative catalysts beyond the minimal revenue shortfall, the magnitude of the selloff appears disproportionate to the actual earnings quality and beat.
View CLBT →LMRI — Lumexa Imaging Holdings, Inc. Common Stock (-23.3%)
Lumexa Imaging delivered a solid Q2 2026 beat with adjusted EPS of $0.20 versus $0.1483 estimate (+34.9% surprise) on revenue of $264.2M versus $263.1M expected (+0.4% beat), while same-center advanced volume growth remained healthy at 5.2% consolidated and 4.9% system-wide. Management reaffirmed full-year revenue guidance ($1.045B–$1.097B) and adjusted EPS guidance ($0.71–$0.77), narrowing Adjusted EBITDA guidance to $235M–$241M from $234M–$242M with the midpoint unchanged at $238M. However, the company did acknowledge that adjusted EBITDA growth slowed from 7% to 4% when accounting for ~$7M in new public company costs not incurred in 2025, and Adjusted EBITDA margin compressed 100bps to 21.4% from 22.4% year-over-year, though this was partly offset by strong operational momentum with six new health system partnerships announced. A 23.3% stock plunge on a 35% EPS beat, reaffirmed FY guidance, and maintained strategic expansion trajectory appears disproportionate—the margin compression and public-company-cost headwinds are real but were disclosed transparently and don't negate the quarter's operational strength or the unchanged midpoint guidance.
View LMRI →STUB — StubHub Holdings, Inc. (-21.5%)
StubHub reported a significant EPS miss of 63.9% (actual $0.0386 vs. estimate $0.1067) but delivered an 11.6% revenue beat ($573.1M vs. $513.3M), record GMS of $3.1B (+34% YoY), and adjusted EBITDA of $105.7M (+94% YoY) with an 18% margin—up 600 basis points. Management also raised full-year GMS guidance to $10.1–$10.3B and reiterated adjusted EBITDA guidance of $400–$420M, while strengthening the balance sheet with $200M in debt reduction YTD and improving net leverage to 3.0x from 4.5x. The 21.5% stock decline appears disproportionate to the underlying operational performance: while the GAAP EPS miss is severe, it reflects non-operating headwinds (higher general and administrative expenses, interest costs) rather than core business deterioration, and the company is demonstrating accelerating profitability, cash generation ($309.7M free cash flow, +3,089% YoY), and structural deleveraging. The revenue beat and margin expansion on record GMS growth, coupled with raised guidance, should typically drive a modest positive reaction or at worst a modest pullback—not a 21% washout that implies a material business deceleration that the numbers simply do not support.
View STUB →SECZ — Securitize Corp. (-23.1%)
Securitize reported Q2 2026 revenue of $14.4 million versus an estimate of $20.6 million (a 30% miss), with an EPS of −$2.37 versus an estimate of −$0.15 (a 1,450% miss in the negative direction). The core operational story is genuinely positive: tokenized AUM hit a record average of $4.3 billion (+16% YoY), transaction volume surged 147% to $5.3 billion, and the company announced marquee partnerships with Computershare, Continental, Cantor Fitzgerald, and Jump Trading, plus FINRA approval for expanded broker-dealer capabilities. However, the company posted a net loss of $21.7 million (versus $5.5 million in the prior year) and swung from +$1.8 million adjusted EBITDA to −$5.5 million, driven by a $29.3 billion swing in fair-value changes on option liabilities and $4.3 billion on SAFEs—non-cash mark-to-market charges related to its recent NYSE IPO on July 2nd. The 23% stock decline appears partially justified by the severe revenue and earnings misses, but those misses are heavily distorted by accounting revaluations tied to the IPO itself rather than operational deterioration. The company ended with $350 million cash and zero debt, contrary to financial distress, and its business metrics (AUM growth, partnerships, regulatory approvals) remain industry-leading. The move likely conflates post-IPO volatility valuations with underlying business momentum.
View SECZ →OTLK — Outlook Therapeutics, Inc. (-28.2%)
Outlook Therapeutics reported earnings on August 13, 2026, but the SEC filing provides no specific EPS, revenue beat/miss percentages, or forward guidance changes—only a risk-factor disclosure noting the company recognized $1.4 million in LYTENAVA revenue during fiscal 2025 and received FDA approval in July 2026 but has not yet launched in the U.S. market. The filing explicitly states "substantial doubt about our ability to continue as a going concern," with only $7.7 million in cash as of March 31, 2026, plus $9.1 million in recent offerings, leaving funding only through September 2026, and $19.8 million in debt to Atlas Sciences due June 2027. Without disclosed earnings metrics or forward-guidance deltas, it is impossible to assess whether the 28.2% stock decline is proportionate to business deterioration or a market repricing of existential survival risk; the severity of the going-concern warning and imminent cash depletion may justify a sharp selloff, but the absence of concrete quarterly results or guidance makes calibrating the magnitude extremely difficult.
View OTLK →BRAG — Bragg Gaming Group Inc. (-20.6%)
Bragg Gaming Group reported a minor EPS miss of -3.5% (actual -0.13 vs. estimate -0.1256) and a modest revenue shortfall of -2.1% (actual $26.16M vs. estimate $26.72M), delivering near-consensus results with no material guidance change disclosed in available sources. A 20.6% stock decline on such modest misses—where the company came within a few cents on earnings and less than $600K on revenue—appears disproportionate to the magnitude of the operational disappointment. However, the lack of specific forward guidance, management commentary, or operational details in the available source material prevents full assessment of whether underlying business trends (margins, customer metrics, or market headwinds) justified a more severe repricing. Without visibility into whether management downgraded near-term outlook or disclosed deteriorating fundamentals beyond these quarterly figures, the move reads as an outsized reaction to marginal quarterly shortfalls, though material context may be missing.
View BRAG →LESL — Leslie's, Inc. (-40.9%)
Leslie's reported Q3 adjusted EPS of $3.96, missing consensus by 18.5% ($4.86 estimate), while revenue came in at $458.5 million versus $503.2 million expected, a 9% miss. The company withdrew full-year guidance citing macroeconomic softness and announced it is exploring strategic alternatives including potential deleveraging transactions, signaling serious balance-sheet distress. Q3 showed comparable sales declined 6.2% year-over-year, gross margin compressed 310 basis points to 36.5%, and adjusted EBITDA fell 32% to $55.7 million, while year-to-date results are deeply negative with adjusted EBITDA of $(11.4) million versus positive $16.2 million prior year—indicating the company has swung from profitable to unprofitable on a nine-month basis. Management explicitly acknowledged "macroenvironmental remains challenging" and signaled they are exploring debt restructuring with financial stakeholders, which typically precedes material equity dilution or restructuring risk. A 41% stock decline on an 18.5% EPS miss, combined with guidance withdrawal, margin compression of 310 bps, year-to-date EBITDA swing of $27.6 million to negative, and explicit disclosure of going-concern-adjacent strategic alternatives, reflects a material deterioration in the business trajectory and balance-sheet stability that extends well beyond the single-quarter print.
View LESL →